default author photo

Nong Yang

Central South University - Department of Medical Oncology

China

  • Central South University - Department of Medical Oncology

SCHOLARLY PAPERS

11

DOWNLOADS

678

TOTAL CITATIONS

10

Scholarly Papers (11)

Actions:
Email selected abstracts
1.

Overall Survival According to Time-of-Day of Treatment Administration in 713 Patients Receiving Immunochemotherapy as First Line Treatment Protocol for Advanced Non-Small Cell Lung Cancer: A Bicentric Bicontinental Study

Number of pages: 25 Posted: 18 Oct 2024
Zhe Huang, Abdoulaye Karaboué, Liang Zeng, Adrien Lecoeuvre, Lemeng Zhang, Xiao-Mei Li, Haoyue Qin, Gabrielle Danino, Feng Yang, Marie-Sara Malin, Li Deng, Marthe Rigal, Hong Liu, Xiang Chen, Qinqin Xu, Lamiae Grimaldi, Thierry Collon, Jing Wang, René Adam, Nong Yang, Boris Duchemann, Yongchang Zhang and Francis Lévi
Central South University - Hunan Cancer Hospital, University of Paris-Saclay, Central South University - Department of Medical Oncology, University of Paris-Saclay, Central South University - Hunan Cancer Hospital, University of Paris-Saclay, Central South University - Hunan Cancer Hospital, Université Paris XIII Nord - Avicenne Hospital, Central South University - Hunan Cancer Hospital, Université Paris XIII Nord - Avicenne Hospital, Central South University - Hunan Cancer Hospital, Assistance Publique-Hôpitaux de Paris - Hôpitaux Universitaires Paris Seine Saint-Denis, Central South University - Department of Dermatology, Central South University - Department of Dermatology, Qinghai Provincial People's Hospital - Department of Medical Oncology, University of Versailles - Clinical Research Unit, Northeastern Great Paris Hospital Group, Central South University - Hunan Cancer Hospital, University of Paris-Saclay, Central South University - Department of Medical Oncology, Hôpital Avicenne (APHP), Central South University - Department of Medical Oncology and University of Paris-Saclay - UPR “Chronothérapie, Cancers, et Transplantation”
Downloads 118 (608,822)

Abstract:

Loading...

Circadian rhythms, Chronotherapy, Immune checkpoint inhibitors, Time of day of administration, Lung cancer, Immuno-chemotherapy, Chronopharmacology, Circadian medicine

2.

Gut Microbiome Is Associated with the Anti-PD-1 Immunotherapy Outcomes in Advanced Non-Small-Cell Lung Cancer

Number of pages: 27 Posted: 06 Jan 2023
Yawen Bin, Fan Tong, Yongchang Zhang, Ruiguang Zhang, Hongxia Zhou, Liang Zeng, Pian Liu, Sheng Zhang, Ye Wang, Nong Yang and Xiaorong Dong
Huazhong University of Science and Technology - Cancer Centre, Huazhong University of Science and Technology - Cancer Centre, Central South University - Department of Medical Oncology, Huazhong University of Science and Technology - Cancer Centre, Huazhong University of Science and Technology - Cancer Centre, Central South University - Department of Medical Oncology, Huazhong University of Science and Technology - Cancer Centre, Huazhong University of Science and Technology - Cancer Centre, Huazhong University of Science and Technology - Cancer Centre, Central South University - Department of Medical Oncology and Huazhong University of Science and Technology - Cancer Centre
Downloads 92 (742,061)

Abstract:

Loading...

NSCLC, gut microbiome, immunotherapy, prospective, Schaalia

3.

Antitumor Activity of First-Line Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancers: A Large Cohort, Multi-Center, Retrospective Study

Number of pages: 27 Posted: 28 Oct 2020
Yongchang Zhang, Liang Zeng, Xiangyu Zhang, Ruiguang Zhang, Yizhi Li, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Hao Liu, Fan Tong, Xiaorong Dong, Renan Jin, Yu Zeng, Qinglin Li, Yang Li, Chunwei Xu, Jianbo Wang, Jun Liu, Wenxian Wang, Yongxi Song, Jiexia Zhang, Zhengbo Song, Ignatius Sai-Hong Ou and Nong Yang
Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Central South University - Department of Medical Oncology, Qinghai Provincial People's Hospital - Department of Medical Oncology, Central South University - Department of Medical Oncology, Burning Rock Biotech, Burning Rock Biotech, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Tongji University School of Medicine - Department of Pathology, Department of Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Department of Genetics, School of Life Science, Anhui Medical University, Chinese Academy of Sciences (CAS) - Institute of Basic Medicine and Cancer (IBMC), Department of Radiotherapy; Qilu Hospital of Shandong University, Huazhong University of Science and Technology - Cancer Center, Chinese Academy of Sciences (CAS) - Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Department of Surgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, First Affiliated Hospital, China Medical University, Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Chinese Academy of Sciences (CAS) - Department of Medical Oncology, University of California, Irvine - Chao Family Comprehensive Cancer Center and Central South University - Department of Medical Oncology
Downloads 72 (860,052)

Abstract:

Loading...

ROS1 fusion, ROS1 gene rearrangements, crizotinib, non-CD74 ROS1 fusions, crizotinib resistance mechanism

4.

Efficacy and Safety of IBI351 Monotherapy in KRASG12C-Mutated Metastatic Colorectal Cancer: Results from a Pooled Analysis of Phase I Part of Two Studies

Number of pages: 17 Posted: 15 Oct 2024
Ying Yuan, Yanhong Deng, Yongdong Jin, Zeng-Qing Guo, Yueyin Pan, Cunji Wang, Zhiwu Wang, Yi Hu, Dong Hua, Xiangjiao Meng, Zhiye Zhang, Mingfang Zhao, Xiaorong Dong, Dingzhi Huang, Xiaoyan Li, Lian Liu, Meili Sun, Huijuan Wang, Xiuwen Wang, Nong Yang, Mingjun Zhang, Sheng Hu, Dongde Wu, Jingjing Huang, Sujie Zhang, Mengna Huang and Ke-feng Ding
Zhejiang University, Sun Yat-sen University (SYSU), Sichuan Cancer Hospital, Fujian Medical University - Department of Medical Oncology, Anhui Provincial Hospital, Hunan Traditional Chinese Medical College, Tangshan People’s Hospital, Government of the People's Republic of China - Department of Oncology, Nanjing Medical University - Department of Oncology, Shandong Provincial Cancer Hospital, Henan University of Science and Technology, China Medical University, Huazhong University of Science and Technology, Tianjin Medical University - Tianjin Cancer Institute, Capital Medical University, Shandong University, Shandong First Medical University, Zhengzhou University, Shandong University, Central South University - Department of Medical Oncology, Anhui Medical University, Huazhong University of Science and Technology - Department of Medical Oncology, Huazhong University of Science and Technology - Hubei Cancer Hospital, Innovent Biologics (Suzhou) Co. Ltd, Innovent Biologics (Suzhou) Co. Ltd, Innovent Biologics (Suzhou) Co. Ltd and Zhejiang University - Department of Colorectal Surgery and Oncology
Downloads 69 (891,180)

Abstract:

Loading...

IBI351, KRASG12C, colorectal cancer, efficacy

5.

Potential Utility of Albumin-Bilirubin (ALBI) and Body Mass Index (BMI)-Based Logistic Model to Predict Survival Outcome in Non-Small Cell Lung Cancer with Liver Metastasis Treated with PD-1 Inhibitor

Number of pages: 52 Posted: 21 Aug 2023
Lianxi Song, Qinqin Xu, Ting Zhong, Wenhuan Guo, Shaoding Lin, Wenjuan Jiang, Zhan Wang, Li Deng, Zhe Huang, Haoyue Qin, Huan Yan, Xing Zhang, Fan Tong, Ruiguang Zhang, Zhaoyi Liu, Lin Zhang, Xiaorong Dong, Ting Li, Chao Fang, Xue Chen, Jun Deng, Jing Wang, Nong Yang, Liang Zeng and Yongchang Zhang
Central South University - Department of Medical Oncology, Qinghai Provincial People's Hospital - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Shanghai Jiao Tong University (SJTU), Hunan University of Medicine - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Huazhong University of Science and Technology - Cancer Center, Huazhong University of Science and Technology - Cancer Centre, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Huazhong University of Science and Technology - Cancer Centre, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology and Central South University - Department of Medical Oncology
Downloads 58 (989,921)

Abstract:

Loading...

albumin-bilirubin grading system, immune checkpoint inhibitor, liver metastasis non-small cell lung cancer, prognostic markers

6.

Landscape of Next Generation Sequencing in Screening Accurate Benefit Population for First Line Crizotinib in ALK Rearranged Advanced Non-Small Cell Lung Cancer

Number of pages: 21 Posted: 24 Jan 2019
Liang Zeng, Chunhua Zhou, Yizhi Li, Lin Wu, Chen Xia, Wenjuan Jiang, Yijuan Hu, Dehua Liao, Lili Xiao, Li Liu, Haiyan Yang, Yi Xiong, Rui Guan, Yongchang Zhang and Nong Yang
Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Second Chest Cancer Unit, Central South University - Department of Pharmacy, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Pharmacy, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology and Central South University - Department of Medical Oncology
Downloads 57 (1,000,027)
Citation 4

Abstract:

Loading...

NGS, Ventana, ALK, Fusion partners, Crizotinib

7.

Bevacizumab Plus Erlotinib in Chinese Patients with Untreated, EGFR-Mutated, Advanced NSCLC (ARTEMIS-CTONG1509): A Multicenter Phase 3 Study

Number of pages: 56 Posted: 19 Dec 2020
Qing Zhou, Ying Cheng, Yun-Peng Liu, Gong-Yan Chen, Jiu-Wei Cui, Nong Yang, Yong Song, Xiao-Ling Li, Shun Lu, Jian-Ying Zhou, Zhi-Yong Ma, Shi-Ying Yu, Cheng Huang, Yong-Qian Shu and Yi-Long Wu
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Jilin Provincial Tumor Hospital - Department of Thoracic Oncology, China Medical University - Department of Medical Oncology, Harbin Medical University - Cancer Hospital, Jilin University (JLU) - Cancer Center, Central South University - Department of Medical Oncology, Nanjing Military General Hospital - Respiratory Medicine, China Medical University - Medical Oncology Department of Thoracic Cancer, Shanghai Jiao Tong University (SJTU) - Medical Oncology, Zhejiang University - Respiratory Medicine, Henan Cancer Hospital - Respiratory Medicine, Huazhong University of Science and Technology (Formerly Tongi Medical University) - Medical Oncology, Fujian Cancer Hospital - Medical Oncology, Nanjing Medical University - Department of Oncology and Southern Medical University
Downloads 54 (1,031,043)
Citation 5

Abstract:

Loading...

bevacizumab, EGFR mutation, epidermal growth factor inhibitor, erlotinib, non-small-cell lung cancer, vascular endothelial growth factor inhibitor

8.

PD-1 Blockade Plus Chemotherapy for EGFR-Mutant, EGFR Tyrosine Kinase Inhibitor-Pretreated Non-Small Cell Lung Cancer: A Multicenter Retrospective Study on Efficacy and Biomarker Exploration

Number of pages: 66 Posted: 31 May 2022
Lianxi Song, Liang Zeng, Qinqin Xu, Wenhuan Guo, Shaoding Lin, Wenjuan Jiang, Zhan Wang, Li Deng, Zhe Huang, Haoyue Qin, Huan Yan, Xing Zhang, Fan Tong, Ruiguang Zhang, Zhaoyi Liu, Lin Zhang, Xiaorong Dong, Nong Yang and Yongchang Zhang
Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Qinghai Provincial People's Hospital - Department of Medical Oncology, Shanghai Jiao Tong University (SJTU) - Department of Pathology, Hunan University of Medicine - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Huazhong University of Science and Technology - Cancer Center, Huazhong University of Science and Technology - Cancer Centre, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Huazhong University of Science and Technology - Cancer Centre, Central South University - Department of Medical Oncology and Central South University - Department of Medical Oncology
Downloads 53 (1,041,696)

Abstract:

Loading...

Non-small cell lung cancer, immune checkpoint inhibitor, EGFR, tyrosine kinase inhibitors, lymphocyte subsets model

9.

Apatinib Plus Vinorelbine in Second Line Treatment Failure Wildtype Advanced Non-Small Cell Lung Cancer (VICTOR): A Phase II Three-Dimensional Co-Culture Platforms-Guided Prospective Study

Number of pages: 33 Posted: 24 Sep 2019
Xiangyu Zhang, Yi Xiong, Qing Xia, Fang Wu, Lingli Liu, Yuling Zhou, Liang Zeng, Chunhua Zhou, Chen Xia, Wenjuan Jiang, Dehua Liao, Lili Xiao, Li Liu, Haiyan Yang, Rui Guan, Kunyan Li, Jing Wang, Lei Guang, Yongchang Zhang and Nong Yang
Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Shanghai Jiao Tong University (SJTU) - Department of Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Hepatology, Central South University - Department of Medical Oncology, Central South University - Department of Pharmacy, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, The University of Texas MD Anderson Cancer Center - Department of Experimental Radiation Oncology, Central South University - Department of Medical Oncology and Central South University - Department of Medical Oncology
Downloads 47 (1,109,210)
Citation 1

Abstract:

Loading...

Three-Dimensional Co-Culture, Apatinib, Vinorelbine, Second Line Treatment Failure, Non-small Cell Lung Cancer, Prospective Study

10.

Apatinib Combined with Vinorelbine in Second Line Treatment Failure Non-Driver Mutation Advanced Non-Small Cell Lung Cancer(VICTOR): A Phase 2, Single-Arm, Prospective Study

Number of pages: 24 Posted: 22 May 2019
Xiangyu Zhang, Yi Xiong, Qing Xia, Fang Wu, Lingli Liu, Yuling Zhou, Liang Zeng, Chunhua Zhou, Chen Xia, Wenjuan Jiang, Dehua Liao, Lili Xiao, Li Liu, Haiyan Yang, Rui Guan, Kunyan Li, Jing Wang, Lei Guang, Yongchang Zhang and Nong Yang
Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Shanghai Jiao Tong University (SJTU) - Department of Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Hepatology, Central South University - Department of Medical Oncology, Central South University - Department of Pharmacy, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, The University of Texas MD Anderson Cancer Center - Department of Experimental Radiation Oncology, Central South University - Department of Medical Oncology and Central South University - Department of Medical Oncology
Downloads 38 (1,209,354)

Abstract:

Loading...

Apatinib, Vinorelbine, Second Line Treatment Failure, Non-small Cell Lung Cancer, Prospective Study

11.

Sintilimab Plus Docetaxel as Second-Line Therapy of Advanced Non-Small Cell Lung Cancer Without Targetable Mutations: A Phase II Efficacy and Biomarker Study

Number of pages: 28 Posted: 25 Apr 2022
Yongchang Zhang, Lianxi Song, Liang Zeng, Yi Xiong, Li Liu, Chunhua Zhou, Haiyan Yang, Zhan Wang, Qing Xia, Wenjuan Jiang, Qinqin Xu and Nong Yang
Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Shanghai Jiao Tong University (SJTU) - State Key Laboratory of Oncogenes and Related Genes, Central South University - Hunan Cancer Hospital, Qinghai Provincial People's Hospital - Department of Medical Oncology and Central South University - Department of Medical Oncology
Downloads 20 (1,459,862)

Abstract:

Loading...

Sintilimab plus docetaxel, NSCLC, CTC-PD-L1, multiplex immunofluorescence